Daiichi Sankyo Co Ltd 2013 IR
The report outlines the Daiichi Sankyo Group's transition to an integrated reporting format, combining its Annual and CSR Reports into the Value Report 2013. It details the Group's Third Mid-term Business Management Plan (FY2013-2017), aiming to establish itself as a Global Pharma Innovator. Key highlights include the launch of innovative treatments like RANMARK and Synriam, and the Group's participation in the United Nations Global Compact. Additionally, the report covers the Group's environmental management achievements, such as a 25.2% reduction in carbon dioxide emissions in Japan compared to fiscal 2007, and its social contribution initiatives globally.
Company: Daiichi Sankyo Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2013
Type: IR
Pages: 100
Back to company
Daiichi Sankyo Co Ltd
Value Report
The report outlines the Daiichi Sankyo Group's transition to an integrated reporting format, combining its Annual and CSR Reports into the Value Report 2013. It details the Group's Third Mid-term Business Management Plan (FY2013-2017), aiming to establish itself as a Global Pharma Innovator. Key highlights include the launch of innovative treatments like RANMARK and Synriam, and the Group's participation in the United Nations Global Compact. Additionally, the report covers the Group's environmental management achievements, such as a 25.2% reduction in carbon dioxide emissions in Japan compared to fiscal 2007, and its social contribution initiatives globally.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2013
Reporting Period
Apr 1, 2012 - Mar 31, 2013
Fiscal Year
2012
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Employees